Periodic Reporting for period 1 - CECM (Centre for New Methods in Computational Diagnostics and Personalised Therapy)
Reporting period: 2017-09-01 to 2018-08-31
• Personalised assessment, diagnosis and treatment, derived from imaging and other clinical data
• New measures of disease (‘biomarkers’), computed from 3D models using FEA2 and CFD
• Access to the entire knowledge-base of medical understanding, constantly updated
• The accelerated introduction of new drugs and devices, using in silico development methods.
The Centre will therefore establish the generic development engine capable of transforming any innovative computational healthcare solution into a deployable clinical reality.
Poland, and in particular Małopolska, are perfectly positioned to play a key role in this new domain of applied computational medicine since Kraków educates large numbers of medical and IT professionals, and routinely engages in interdisciplinary research with Europe’s world-leading in silico research community. Also in Małopolska region there is a high concentration of research hospitals in and around the city, and the entrepreneurial community has recently entered a phase of rapid growth, and this includes life science companies.
The Centre will exploit these advantages to build a world-class facility, attractive to all CDSS developers, and will have a major impact at both regional and national scales, with lasting benefits for Polish and pan-European society.
The main objective of project was to provide comprehensive information about the state-of-the-art in personalized health technologies from the perspective of computational medicine and elaboration the R&D strategy for the Centre. Amongst main tasks within this objective was to review R&D landscape for computational medicine and definition of primary R&D objectives for the new CoE. As the result of those 2 tasks, the report on the latest developments and trends in computational medicine was created. This repot together with the analysis of critical R&D challenges and opportunities helped to create innovation strategy for the Centre and build long term R&D strategy.
When the R&D research has been done consortium tried to conceptualise the business model and respective organisational structure supporting the R&D strategy. The main challenge in this was to select an organisational model of a Centre which would have highly dynamic nature of the domain. During the process, consortium members had to answer several questions connected with elaboration of competitive products and services, defining the target markets and R&D Networks in the new CoE. In this was also essential to create a comprehensive plan for IPR management inside new CoE and among consortium members. Partners have drafted general rules for data management, communication and outreach, accountability, transparency and ethics inside new Centre of Excellence. All the above helped choose and create governance and organisational structure of the new CoE.
The very important objective was also to elaborate the way the Centre should operate from resource management perspective. One of the main tasks was to create the cost structure of the new CoE, devise a funding strategy and income plan for the centre and a comprehensive plan on management of human capital. At the end consortium members were able to come up with a detailed financial plan for the new centre and a comprehensive human capital policy.
All this work aimed to describe the vision and the mission of the Centre, and compiling a convincing, sound and executable Business Plan for the future Centre. At the end the robust business plan for Centre of Excellence for in silico Medicine in Krakow, Poland has been created.
The project itself helped to strengthen the cooperation between all partners which in future will evolve in good and successful cooperation, with many common projects in H2020. The cooperation will took place mainly through the new CoE, which will bring additional benefits to CECM project.
The Centre through its objectives will mitigate the disparities between “widening” and “well-performing” EU countries, by improving research and innovation culture in Poland.